ESR1 and breast carcinoma: In addition, using the Gene Expression-Based Outcome for Breast cancer Online (GOBO) [21] with datasets GSE1456, 3494, 7390, representing a total of 737 breast cancers, no relationship was found between sortilin mRNA abundance and clinicopathological parameters (molecular subtypes, lymph node invasion, ER, PR, HER2).